E
AQST icon

Ergoteles’s Aquestive Therapeutics AQST Stock Holding History

Ergoteles’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-90,900
Closed -$361K – 1187
2021
Q2 		$361K Buy
+90,900
New +$363K 0.01% 977
2021
Q1 		– Sell
-26,400
Closed -$141K – 790
2020
Q4 		$141K Buy
+26,400
New +$158K ﹤0.01% 621

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCL
Bracebridge Capital LLC Boston, Massachusetts $3.73B AUM 33.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LI
Latash Investments Anchorage, Alaska $129M AUM 14.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ergoteles's AQST Position: Q3 2021 in Review

Ergoteles sold out of Aquestive Therapeutics (AQST) in Q3 2021, closing a stake of 90,900 shares — an estimated $361K sold.

Ergoteles first reported a position in AQST in Q4 2020 and held it in 2 quarters. The position peaked at $361K in Q2 2021. 46 funds tracked by Wall St. Rank hold AQST as of Q3 2021.

  • Ergoteles reported no remaining Aquestive Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Ergoteles sold 90,900 Aquestive Therapeutics shares in Q3 2021, an estimated $361K.
  • Ergoteles first reported a position in Aquestive Therapeutics in Q4 2020 and held it in 2 quarters.
  • Ergoteles's Aquestive Therapeutics position peaked at $361K in Q2 2021.
  • 46 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q3 2021.

Based on Ergoteles's 13F filing for Q3 2021, filed 15 Nov 2021.